See analyst estimates and all valuation multiples for Genomics & Personalized Medicine
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $31.5B | 14.3x | -96.3x | |
| $21.9B | 5.1x | 18.4x | |
| $20.8B | 6.5x | 45.4x | |
| $13.7B | 14.2x | -64.2x | |
| $4.6B | n/a | n/a | |
| $4.0B | 9.5x | 102.7x | |
| $3.1B | 21.1x | -7.4x | |
| $3.1B | 6.1x | 23.5x | |
| $2.6B | 2.8x | 15.5x | |
| $2.3B | 4.2x | -1354.3x | |
| $1.8B | 4.7x | -46.1x | |
| $1.6B | 2.6x | -28.8x | |
| $1.6B | n/a | n/a | |
| $1.3B | 2.2x | 18.3x | |
| $1.3B | 214.5x | -11.0x | |
| $957M | 6.1x | -6.6x | |
| $901M | 2.7x | 24.1x | |
| $834M | 2.2x | 22.3x | |
| $719M | 28.9x | n/a | |
| $691M | 0.8x | 22.1x | |
| $648M | 9.2x | -8.2x | |
| $640M | n/a | -5.8x | |
| $592M | 1.9x | 10.9x | |
| $558M | 99.4x | -2.9x | |
| $485M | 1.5x | -86.0x | |
| $438M | 87.1x | n/a | |
| $411M | n/a | -3.5x | |
| $317M | 4.2x | -6.8x | |
| $297M | 3.9x | -6.9x | |
| $296M | n/a | n/a | |
| $279M | n/a | n/a | |
| $273M | 2.9x | n/a | |
| $262M | n/a | -30.8x | |
| $248M | n/a | -1.4x | |
| $230M | 65.2x | -4.2x | |
| $207M | 5.6x | -1.7x | |
| $152M | n/a | n/a | |
| $146M | 2.2x | -3.2x | |
| $109M | 45.8x | -5.0x | |
| $106M | n/a | -1.2x | |
| $100M | 24.0x | -2.0x | |
| $93.6M | 16.7x | n/a | |
| $92.3M | 8.4x | -1.3x | |
| $82.4M | 3.4x | -0.5x | |
| $34.3M | 3.7x | -0.2x | |
| $31.7M | 0.7x | n/a | |
| $26.4M | 4.9x | n/a | |
| $13.4M | n/a | n/a | |
| $11.9M | 0.4x | -0.1x | |
| $11.1M | n/a | n/a | |
| $8.3M | n/a | n/a | |
| $2.9M | n/a | -0.0x | |
| $2.5M | n/a | n/a | |
| -$9.1M | -0.1x | n/a | |
| -$26.3M | -2.2x | n/a | |
| -$76.7M | -2.6x | 0.8x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Genomics & Personalized Medicine